Reference drugs for triple combination test drug in Russia [Design Issues]

posted by PharmCat  – Russia, 2019-11-13 22:25 (1116 d 08:42 ago) – Posting: # 20801
Views: 4,652

❝ i.e. 2 tablets. All of these drugs are reference drugs according to the GRLS system.


❝ What is your opinion which option to choose?


Hello!

Strictly for bioequivalence you should chose drug from register that have label "Reference drug". If no such drug - you should make
efficacy trial.

I heard there was a case when drug was registered in EU and BE in Russia was performed with separate reference drugs - but now this case is not approvable, but some companies try to do this.

If say strict - both cases is wrong.

Complete thread:

UA Flag
Activity
 Admin contact
22,427 posts in 4,694 threads, 1,598 registered users;
14 visitors (0 registered, 14 guests [including 11 identified bots]).
Forum time: 07:08 CET (Europe/Vienna)

Operational hectic replaces
intellectual calms.    Alexander Huiskes

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5